Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Intertrade Co.,Ltd. (3747.T)
Tokyo, JP
Intertrade Co.,Ltd. is a Japanese firm that delivers a range of services across the financial, business, and healthcare sectors. Their technological offerings for the financial industry include sophisticated systems for securities trading, foreign exchange (forex) margin trading platforms, cryptocurrency asset management solutions, and private exchange infrastructures. For businesses, they provide comprehensive support through integrated management platforms, expert system engineering, and dedicated support center and systems integration (SI) services. Beyond digital solutions, the company also engages in the health and wellness market, developing and marketing health foods and cosmetics, in addition to cultivating specialized functional mushrooms. Intertrade Co.,Ltd. was founded in 1999 and is based in Tokyo, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.19% | +2.10% | -4.29% | -17.79% | -27.86% | -23.65% | +40.68% | +65.43% | +8.72% | +106.95% | -77.19% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Financial - Capital Markets: +19.7%-0.7% Q1'26: +7.4% (vs Q1'25)
-
EPS growth Financial - Capital Markets: +35.3%-48.3% Q1'26: +42.8% (vs Q1'25)
-
FCF margin FCF growth · Financial - Capital Markets: +29.5%-8.6% Q1'26: -3.4% (vs Q1'25)
-
EBIT margin Financial - Capital Markets: +33.5%-8.0% Q1'26: +5.0% (vs Q1'25)
-
ROIC Financial - Capital Markets: +4.0%-24.6% Q1'26: +12.5% (vs Q1'25)
-
Share dilution Financial - Capital Markets: +0.0%+0.0% Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Financial - Capital Markets: -0.30×-1.81× Q1'26: 2.02× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-28 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-25 | B- | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kazuya Nishimoto | President, Chief Executive Officer & Chairman | — | male |
| Toshihiro Naito | GM of Health Care Business Division & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 3747.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
